One of India's biggest drug makers, Ranbaxy Laboratories, revealed that it has initiated a recall of its cholesterol-lowering drug Atorvastatin calcium in the United States after finding that some of the batches may contain small amounts of glass.
The company said that the recall could lead to temporary disruption in supply of the drug as it may take up to two weeks for it to complete an investigation.
Analysts are also predicting that the recall will hurt the company financially with share prices seeing a 3.1 percent drop on the Indian markets.
"Ranbaxy... is conducting a voluntary recall for Atorvastatin calcium tablets, in connection with its 10 mg, 20 mg and 40 mg dosage strengths... only with respect to certain select lot numbers... The recall is being conducted at the retail level for such select batches that may contain a foreign substance (small glass particles approximately less than 1 mm in size)", the company said in a statement.